Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain bleed breakthrough? drug may stop hidden seizures

NCT ID NCT02631759

Prevention Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving the seizure drug levetiracetam right away can prevent seizures in people who had a brain bleed (hemorrhagic stroke). About 50 adults with a recent brain bleed received either the drug or a placebo. The goal was to see if the drug could reduce seizures detected by brain monitoring, which might improve recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

50 people

The number who actually took part.

Started

Oct 2016

Finished

Jun 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age greater than 18 years with no upper age limit * Competent adult patient. * Patient affiliated to the French National Health Insurance. * Patient with supratentorial spontaneous intracerebral hemorrhage diagnosed by CT or MRI * Early neurological symptoms less than 24 hours * NIHSS score on admission between 5 and 25 * Informed consent given by the patient or his legal representative Exclusion Criteria: * Inaugural Seizures ( at the onset of symptoms associated with intracerebral hemorrhage ) * Seizures occurring between the inclusion of the patient and the start of the EEG * Other Intracerebral hemorrhage infratentorial , post-traumatic , related to a vascular malformation or an underlying tumor and secondarily hemorrhagic cerebral infarction * Current antiepileptic treatment when intracerebral hemorrhage , or a history of epilepsy * Modified Rankin Scale before intracerebral hemorrhage \> 1 (indicating a preexisting disability) * Serious illness which can affect the prognosis within 3 months * Severe renal impairment ( creatinine clearance \<30 ml / min) * Pregnancy, lactation * Known hypersensitivity to levetiracetam or other pyrrolidone derivatives , or any of the excipients. * Untreated severe depression , psychotic disorders * Lactose Intolerance * Patient under measuring socio- legal protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute intracerebral haemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute intracerebral haemorrhage

Contacts and locations

Locations

  • Department of functional neurology and epileptology

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.